THE WIRE · № 79254
SciBase secures first payer coverage with Highmark, marking a major commercial inflection point
01 THE MACHINE READ
WHY IT MATTERS.
First payer coverage for a skin-cancer detection device opens a US reimbursement path, the key gate to commercial adoption.
Reimbursement is the gate to medtech commercialization
Further payer policies or US sales data
Single regional payer; adoption may stay slow
FULL DISPATCH
STOCKHOLM, October 14, 2026 /PRNewswire/ --SciBase Holding AB ("SciBase") (STO: SCIB) a leader in advanced technology for the detection and prevention ofskin disease, announced today that Nevisense has received its first positive medical policy from Highmark Blue Cross Blue Shield, one of...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Kedrion: at ESID 2026, experts call for earlier diagnosis and greater awareness as Secondary Immunodeficiencies continue to rise2026-10-14 08:00 UTC
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda2026-10-14 08:07 UTC
J&J raises its forecast again. CFO Joe Wolk on what's driving it2026-10-13 21:30 UTC
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)2026-10-14 02:17 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.